biopolitics
With Covishield in my body, I feel like there is a capillary tube erupting from the Ministry of Health and Family Welfare, and its panoply of attendant bodies vis-à-vis India’s COVID-19 response, soaring across the length of India and plunging into my veins, somewhere in Bangalore. And with every
antimicrobial resistance
Maybe it’s not a coincidence that India is today the site of the world’s largest COVID-19 outbreak and the world’s most prominent source of antimicrobial resistant (AMR) pathogens, a.k.a. ‘superbugs’. The former fiasco is the product of failures on multiple fronts – including policy, infrastructure, logistics,
2020
You know when you’re cooking a packet of Maggi noodles in a saucepan, and you haven’t used enough water or don’t move the stuff soon enough from the pan to a plate once it’s done cooking, and you’re basically left with a hot lump of
basic amenities
I still see quite a few journalists in India refer to “super-spreaders” vis-à-vis the novel coronavirus – implying that some individuals might be to blame for ‘seeding’ lots of new infections in the community – instead of accommodating the fact that simply breathing out a lot of viruses doesn’t suffice to
anti-masker
For a few days last week, before the mail-in votes had been counted in the US, the contest between Joe Biden and Donald Trump seemed set for a nail-biting finish. In this time a lot of people expressed disappointment on Twitter that nearly half of all Americans who had voted
alcohol
Most of the shops I visit to purchase my supplies dispense an alcohol-based hand-sanitiser at the point of entry and have a person stationed there to check customers’ body temperature with a contactless thermal gun. They used to point the gun at the forehead but of late many of them
anti-vaxxer
First, there was light news of a vaccine against COVID-19 nearing the end of its phase 3 clinical trials with very promising results, accompanied with breezy speculations (often tied to the stock prices of a certain drug-maker) about how it’s going to end the pandemic in six months. An
azithromycin
Kiran Mazumdar-Shaw is the head of Biocon, a company headquartered in Bengaluru and which has repurposed a drug called itolizumab – already approved to help manage severe chronic psoriasis in different markets – to manage cytokine release syndrome (CRS) in COVID-19 patients. Setting aside CRS’s relevance in the COVID-19 pathology (considering
Bharat Biotech
If you’re looking for a quantification (although you shouldn’t) of the extent to which science is being conducted by press releases in India at the moment, consider the following list of studies. The papers for none of them have been published – as preprints or ‘post-prints’ – even as the
Biocon
Apparently (and surprisingly) The Telegraph didn’t allow Dinesh Thakur to respond to an article by Biocon employee Sundar Ramanan, in which Ramanan deems Thakur’s article about the claims to efficacy of the Biocon drug Itolizumab not being backed by enough data to have received the DCGI’s approval
COVID-19
What does the term ‘super-spreader’ mean? According to an article in the MIT Tech Review on June 15, “The word is a generic term for an unusually contagious individual who’s been infected with disease. In the context of the coronavirus, scientists haven’t narrowed down how many infections someone
COVID-19
While I’m all for a bit of triumphalism when some component of conventional publication vis-à-vis scientific research – like pre-publication anonymous peer review – fails, and fails publicly, I spotted an article in The Conversation earlier today that I thought crossed a line (and not in the way you think). In
